This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07648225 |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Sponsor | The United Bio-Technology (Hengqin) Co., Ltd. |
| Enrollment | 600 participants |
| Design | Interventional, Randomized, Parallel, Double-blind, Placebo-controlled |
| Conditions | Obesity; Overweight |
| Interventions | UBT251 Injection 4.0 mg; UBT251 Injection 6.0 mg; matching placebos |
| Start | Jul 31, 2026 |
| Primary completion | Sep 29, 2027 |
| Study completion | Nov 3, 2027 |
| Results posted | Not yet |
| Registry last updated | Not stated |
Compounds on this site that cite this trial
What the registry says the trial is about
Randomized, double-blind, parallel, placebo-controlled phase 3 study of UBT251 injection in adults with overweight or obesity. The registry lists 4.0 mg and 6.0 mg arms.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percentage change in body weight from baseline after 52 weeks of treatment | Week 52 |
8 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UBT251 Safety, Tolerability and Efficacy in Overweight or Obesity (Novo Nordisk Phase 2) (Phase 2 NCT07395687)
- UBT251 Injection Phase II Clinical Study (CKD) (Phase 2 NCT07134335)
- UBT251 Injection Phase II Study (Overweight or Obesity) (Phase 2 NCT07177469)
- A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the (Phase 1 NCT07710729)
- A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood (Phase 1 NCT07710768)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
